Botulism
Uncommon disease caused by preformed exotoxins produced by Clostridium
botulinum
Aetiology
- disease caused mostly be type A, B and E exotoxin
- spores are moderately resistant to heat (ie they withstand boiling for several
hours
- vast majority food-bourne. Outbreaks largely due to home-preserved vegetables
(type A), meat (B) or fish (E)
- other high risk foods include low acid fruit and condiments
- wound botulism (rare) due to contamination of wound with soil containing type
A or B organisms
- chronic IV drug abusers at risk
Pathophysiology
- exotoxin absorbed in gut and carried to cholinergic nerves at NMJ, post
ganglionic nerve endings and autonomic ganglia to which it binds irreversibly
- toxin enters nerve endings and interferes with ACh release
Clinical features
- usually 3 day incubation after ingestion of toxin. Range 12h-16 days
- GI symptoms (food-bourne botulism only): nausea, vomiting, abdo pain,
diarrhoea or constipation
- ocular symptoms: blurred vision, mydriasis, diplopia, ptosis
- dry mouth
- dysphagia
- impaired gag, facial and tongue weakness
- generalised weakness. Progresses in a symmetrical descending fashion. Reflexes
normal/decreased
- severe cases: respiratory insufficiency and flaccid weakness of limbs
Differential diagnosis
- other causes of food poisoning
- myasthenia
- GBS
Investigations
- detection of toxin in patient or food
- CSF normal apart from mild elevation of CSF protein in a few cases
- edrophonium test -ve although transient less impressive responses may be seen
in botulism patients
- ECG: may be minor conduction disturbances and non-specific T wave and ST
changes
- nerve conduction normal
- EMG: presynaptic block in affected muscles in only 1/3
- detection of Cl botulinum in stool considered confirmatory
Management
- intubation and ventilation: if bulbar palsy significant or if VT < 10-15
ml/kg in association with hypercarbia and hypoxia. Risk of respiratory failure
greatest in first 2 days of hospitalization
- correct fluid and electrolyte imbalance
- in absence of profound ileus, removal of unabsorbed toxin can be attempted
with water, saline or cathartic enemas. Avoid Mg containing preparations
- antitoxin. If symptoms are severe and toxin type is known given monovalent
antitoxin. Otherwise equine trivalent antitoxin. Dose can be repeated 4 hrly if
patient continues to deteriorate Efficacy of antitoxin in humans not proven in
controlled studies except for type E toxin illness. Hypersensitivity reactions
occur in 9% and therefore antitoxin should not be used in mild cases. History of
atopic illness or previous administration of equine serum are relative
contraindications. Full resuscitation facilities should be available
- guanidine enhances release of ACH from nerve terminals and appears to be
particularly effective in decreasing ocular weakness. May be more appropriate in
mild cases than antitoxin
- antibiotics only for specific infectious complications. Penicillin generally
given. Efficacy unproven
- wound debridement
Prognosis
- most patients improve within a week or so
- small minority require ventilatory support
- factors associated with poorer prognosis: short incubation period, early
involvement of cranial nerves and respiratory muscles, increased age and ? Asian
race
- ICU survival rate should be high and outlook for complete recovery good
- general weakness, mild cranial palsies, constipation
Infant botulism
- 1 week to 9 months. 95% < 6 months
- type A and B
- honey ingestion considered a risk factor
- spores germinate and produce toxins in infant's gut
- may present with features ranging in severity from constipation to sudden
death
- neuro signs usually appear after 1-3 weeks (weak cry, impaired sucking,
drooling, "floppy" head)
- differential includes: sepsis, infectious mononucleosis, virus infections,
organisms
- toxin rarely detected in serum
- symptomatic treatment
- mortality about 2%
Further reading
Skrowronski GA. Neuromuscular disorders. In Oh TE (ed). Intensive Care
Manual, 4th ed., 1997. Butterworth Heinemann, Oxford. pp 434-9
© Charles Gomersall November 1999
|